GATA1 is overexpressed in patients with essential thrombocythemia and it is normalized by anagrelide treatment

被引：0
|
作者：
Brown, L. [1 ]
Graham, C. [1 ]
Rinaldi, C. R. [1 ,2 ]
机构：
[1] Lincoln Univ, Sch Life Sci, MPN LAB, Lincoln, England
[2] United Lincolnshire Hosp NHS Trust, Dept Haematol, Lincoln, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2014年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
171
引用
收藏
页码：71 / 71
页数：1
相关论文
共 50 条
  • [41] ANAGRELIDE AND FIBROBLAST GROWTH FACTOR-2 LEVELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
    Cacciola, R.
    Di Francesco, E.
    Ferlito, C.
    Pezzella, F.
    Cacciola, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 410 - 410
  • [42] GATA1 IS UP-REGULATED IN PATIENT AFFECTED BY ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA BUT NOT IN PRIMARY MYELOFIBROSIS OR CHRONIC MYELOGENOUS LEUKEMIA
    Rinaldi, C. R.
    Rinaldi, C. R.
    Ciancia, R.
    Martinelli, V.
    Del Vecchio, L.
    Rinaldi, P.
    Cicchetti, T.
    Giagnuolo, G.
    Brunetti, L.
    Nucifora, G.
    Pane, F.
    Rotoli, B.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 297 - 297
  • [43] GATA1 IS UP-REGULATED IN PATIENT AFFECTED BY ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA BUT NOT IN PRIMARY MYELOFIBROSIS OR CHRONIC MYELOGENOUS LEUKEMIA
    Rinaldi, C. R.
    Martinelli, V
    Rinaldi, P.
    Ciancia, R.
    Del Vecchio, L.
    Cicchetti, T.
    Giagniuolo, G.
    Brunetti, L.
    Nucifora, G.
    Rotoli, B.
    Pane, F.
    HAEMATOLOGICA, 2008, 93 : S39 - S39
  • [44] Follow-up of clinical manifestations and platelet function test in patients with essential thrombocythemia on anagrelide treatment.
    Vassallu, PS
    Goette, NP
    Glembotsky, AC
    Heller, PG
    Kornblihtt, LI
    Lev, PR
    Chazarreta, DC
    Salim, JP
    Laguna, MS
    Marta, RF
    Molinas, FC
    BLOOD, 2005, 106 (11) : 323B - 323B
  • [45] Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide
    Juan Carlos Hernández-Boluda
    Arturo Pereira
    Francisco Cervantes
    Montse Gómez
    Eduardo Arellano-Rodrigo
    Alberto Alvarez-Larrán
    Francisca Ferrer-Marín
    Ana Kerguelen
    José Antonio Márquez
    María Luisa Antelo
    Carles Besses
    Annals of Hematology, 2013, 92 : 771 - 775
  • [46] Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia
    Santaliestra, Marta
    Ferrer-Marin, Francisca
    Alvarez-Larran, Alberto
    ANNALS OF HEMATOLOGY, 2022, 101 (11) : 2563 - 2564
  • [47] Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide
    Carlos Hernandez-Boluda, Juan
    Pereira, Arturo
    Cervantes, Francisco
    Gomez, Montse
    Arellano-Rodrigo, Eduardo
    Alvarez-Larran, Alberto
    Ferrer-Marin, Francisca
    Kerguelen, Ana
    Antonio Marquez, Jose
    Luisa Antelo, Maria
    Besses, Carles
    ANNALS OF HEMATOLOGY, 2013, 92 (06) : 771 - 775
  • [48] Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia
    Marta Santaliestra
    Francisca Ferrer-Marín
    Alberto Alvarez-Larrán
    Annals of Hematology, 2022, 101 : 2563 - 2564
  • [49] Anagrelide in essential thrombocythemia. Evaluation of efficacy and side effects in 44 patients.
    Salvador-Osuna, C
    Mayayo, P
    Besses, C
    Hernandez-Nieto, L
    Giraldo, P
    Fernandez-Mosteirin, N
    Giralt, M
    BLOOD, 2003, 102 (11) : 342B - 342B
  • [50] Anagrelide, a novel platelet reducing agent: The European experience in treatment of 60 patients with essential thrombocythemia or chronic myeloid leukemia
    Petrides, PE
    Beykirch, MK
    Trapp, OM
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 308 - 309
12345